標(biāo)題: Titlebook: Applied Statistics in Biomedicine and Clinical Trials Design; Selected Papers from Zhen Chen,Aiyi Liu,Yi Tsong Conference proceedings 2015 [打印本頁(yè)] 作者: 貶損 時(shí)間: 2025-3-21 19:01
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design影響因子(影響力)
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design影響因子(影響力)學(xué)科排名
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design被引頻次
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design被引頻次學(xué)科排名
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design年度引用
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design年度引用學(xué)科排名
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design讀者反饋
書(shū)目名稱Applied Statistics in Biomedicine and Clinical Trials Design讀者反饋學(xué)科排名
作者: aviator 時(shí)間: 2025-3-21 21:39 作者: condescend 時(shí)間: 2025-3-22 03:22
Derivation of Mathematical Models,l error model assumptions. Extensive simulation studies are conducted to illustrate the effectiveness and the robustness of the proposed methods. A diabetes data set from a diagnostic study is used to demonstrate the application of the new methods.作者: 我還要背著他 時(shí)間: 2025-3-22 06:41 作者: 詞匯記憶方法 時(shí)間: 2025-3-22 11:32 作者: panorama 時(shí)間: 2025-3-22 15:55 作者: intellect 時(shí)間: 2025-3-22 18:27
Group-Sequential Designs When Considering Two Binary Outcomes as Co-Primary Endpointsiscuss sample size recalculation based on observed interim data. Lastly, we discuss a method for hierarchical hypothesis testing with adaptive type I error allocation in group-sequential designs with co-primary endpoints in order to improve the power of the methods.作者: DEMN 時(shí)間: 2025-3-23 00:45 作者: 大包裹 時(shí)間: 2025-3-23 02:01 作者: 小臼 時(shí)間: 2025-3-23 05:47 作者: evaculate 時(shí)間: 2025-3-23 12:03
Jaydeep Yadav,Ken Korzekwa,Swati Nagar of errors are controlled, such as the error of wrongly approving an ineffective drug and the error of labeling false information. With the collective evidence approach, the need of MAPs in individual studies is debated when multiple studies are available.作者: 動(dòng)作謎 時(shí)間: 2025-3-23 14:00
https://doi.org/10.1007/978-1-62703-758-7ectation of the magnitude of regional differences and the statutory requirements in the USA. Examples are presented to illustrate the design and analysis based on our proposed procedure. Using the proposed two-tier procedure with an upfront explicit decision tree can increase the predictability and transparency of the regulatory decision making.作者: 無(wú)禮回復(fù) 時(shí)間: 2025-3-23 18:17
Estimation of ROC Curve with Multiple Types of Missing Gold Standardmulation studies to compare the performance of the proposed method and the existing approaches in the literature. This methodology is motivated from and applied to a study in Alzheimer’s disease (AD), where two reasons of missingness are modeled separately.作者: Detain 時(shí)間: 2025-3-24 01:41 作者: Mendicant 時(shí)間: 2025-3-24 05:41 作者: 埋葬 時(shí)間: 2025-3-24 09:19
A Two-Tier Procedure for Designing and Analyzing Medical Device Trials Conducted in US and OUS Regioectation of the magnitude of regional differences and the statutory requirements in the USA. Examples are presented to illustrate the design and analysis based on our proposed procedure. Using the proposed two-tier procedure with an upfront explicit decision tree can increase the predictability and transparency of the regulatory decision making.作者: Accolade 時(shí)間: 2025-3-24 10:47 作者: RUPT 時(shí)間: 2025-3-24 15:29 作者: 使?jié)M足 時(shí)間: 2025-3-24 22:03
Treatment Effect Estimation in Adaptive Clinical Trials: A Reviewas this research area has not been widely explored. In this chapter, we would like to discuss the impact of adaptation on the treatment effect estimation and compare some adjustment techniques in the adaptive trials based on simulation results.作者: GIDDY 時(shí)間: 2025-3-24 23:39 作者: Kidney-Failure 時(shí)間: 2025-3-25 07:17 作者: 錫箔紙 時(shí)間: 2025-3-25 08:05 作者: LASH 時(shí)間: 2025-3-25 15:32
Derivation of Mathematical Models,bability for observing a sufficient magnitude of response rate at the end of enriched enrollment phase given the observed data at an interim look. The method is applied to derive futility stopping rules, and the sensitivity of the futility stopping rules is examined based upon the choice of prior di作者: penance 時(shí)間: 2025-3-25 18:58 作者: 咯咯笑 時(shí)間: 2025-3-25 20:06
Enzyme Kinetics of PAPS-Sulfotransferasernative hypotheses for both plausible endpoints. Here, we explore characteristics of the design when the alternative hypothesis for only one of the two endpoints is true, and the treatment effect for another endpoint is null (an extremely worst case) or lower than what was anticipated per trial desi作者: PAD416 時(shí)間: 2025-3-26 02:57
Jaydeep Yadav,Ken Korzekwa,Swati Nagarility of study success (PrSS) or probability of success (POS). We discuss the important role that PrSS can play in clinical trial design and decision making throughout medical product development. A few examples are given for illustration.作者: inveigh 時(shí)間: 2025-3-26 08:08 作者: 帳單 時(shí)間: 2025-3-26 11:58 作者: nugatory 時(shí)間: 2025-3-26 16:29 作者: cardiopulmonary 時(shí)間: 2025-3-26 17:32 作者: 正式通知 時(shí)間: 2025-3-26 21:35
Bayesian Functional Mixed Models for Survival Responses with Application to Prostate Cancerwhich not only allows dimension reduction of the parameter space but also allows efficient sampling from the conditional distributions. We illustrate our approach with a recent prostate cancer clinical trial study.作者: Infantry 時(shí)間: 2025-3-27 05:00
Bayesian Predictive Approach to Early Termination for Enriched Enrollment Randomized Withdrawal Triabability for observing a sufficient magnitude of response rate at the end of enriched enrollment phase given the observed data at an interim look. The method is applied to derive futility stopping rules, and the sensitivity of the futility stopping rules is examined based upon the choice of prior di作者: Inflamed 時(shí)間: 2025-3-27 05:55
Group Sequential Methods for Comparing Correlated Receiver Operating Characteristic Curves and derive the asymptotic covariance structure for comparative ROC statistics. Relating the difference between empirical ROC curves to the Kiefer process, we also show these results can be used to conduct a GSD using standard software.作者: Malcontent 時(shí)間: 2025-3-27 11:01
Some Characteristics of the Varying-Stage Adaptive Phase II/III Clinical Trial Designrnative hypotheses for both plausible endpoints. Here, we explore characteristics of the design when the alternative hypothesis for only one of the two endpoints is true, and the treatment effect for another endpoint is null (an extremely worst case) or lower than what was anticipated per trial desi作者: colloquial 時(shí)間: 2025-3-27 14:02 作者: 慟哭 時(shí)間: 2025-3-27 19:30 作者: CURL 時(shí)間: 2025-3-27 23:15 作者: 藝術(shù) 時(shí)間: 2025-3-28 05:49 作者: 偶然 時(shí)間: 2025-3-28 08:53
Bayesian Design of Noninferiority Clinical Trials with Co-primary Endpoints and Multiple Dose Comparpproach has the potential of power increase and hence sample size reduction due to the incorporation of the historical data and the correlation structure among multiple co-primary endpoints while it still maintains the family-wise type I error control without additional multiplicity adjustment. In t作者: 無(wú)法解釋 時(shí)間: 2025-3-28 12:28 作者: ATRIA 時(shí)間: 2025-3-28 17:53 作者: Kindle 時(shí)間: 2025-3-28 20:08 作者: 無(wú)可爭(zhēng)辯 時(shí)間: 2025-3-29 01:24 作者: receptors 時(shí)間: 2025-3-29 04:43
Nonparametric Covariate Adjustment for the Youden Indexpular summary index of the ROC curve. In some diagnostic studies, it is believed that the impact of covariates might influence the accuracy of the diagnostic test. In regards to this consideration, we propose nonparametric estimates for the YI with covariate adjustment for the test results under het作者: Nonporous 時(shí)間: 2025-3-29 11:15 作者: 大暴雨 時(shí)間: 2025-3-29 12:23 作者: ethereal 時(shí)間: 2025-3-29 17:37
Collective Evidence in Drug Evaluationicity adjustments within one study to control the type I error rate. The use of multiplicity adjustment procedures (MAPs) sometimes leads to conclusions that may not seem logical. As drug efficacy evaluation involves aspects such as assessing efficacy, selecting optimal doses, and labeling claims, i作者: paltry 時(shí)間: 2025-3-29 21:49 作者: 無(wú)底 時(shí)間: 2025-3-30 01:51 作者: 爵士樂(lè) 時(shí)間: 2025-3-30 07:58
Inferiority Index, Margin Functions, and Hybrid Designs for Noninferiority Trials with Binary Outcomiateness of a fixed margin. The two-step fixed margin approach recommended in the Food and Drug Administration (FDA) guidance to industry on NI trials (US FDA, Guidance to industry: non-inferiority clinical trials, 2010) relies on the availability of relevant historical data and expert clinical know作者: Certainty 時(shí)間: 2025-3-30 11:41 作者: Gudgeon 時(shí)間: 2025-3-30 14:32
Issues in the Use of Existing Data: As Controls in Pre-Market Comparative Clinical Studies clinical studies also play an important role in the evaluation in both premarket and postmarket settings. Such observational comparative studies could be concurrent or nonconcurrent depending on the timing when patients get treated. A nonconcurrent control group could be formed from patients with e作者: Insul島 時(shí)間: 2025-3-30 20:22 作者: 債務(wù) 時(shí)間: 2025-3-30 21:37 作者: Uncultured 時(shí)間: 2025-3-31 03:17 作者: STING 時(shí)間: 2025-3-31 08:45 作者: Sciatica 時(shí)間: 2025-3-31 11:11 作者: 座右銘 時(shí)間: 2025-3-31 13:21 作者: 記憶法 時(shí)間: 2025-3-31 18:26
The Effect of Substrate Concentration,a control regimen. Traditionally, the non-inferiority hypothesis is tested using frequentist methods, e.g., comparing the lower bound of 95?% confidence interval with a pre-specified non-inferiority margin. The analyses are often based on maximum likelihood methods. Recently, Bayesian approaches hav
